Comparative Pharmacology
Head-to-head clinical analysis: AZSTARYS versus METADATE ER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZSTARYS versus METADATE ER.
AZSTARYS vs METADATE ER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AZSTARYS is a prodrug of dexmethylphenidate, a central nervous system stimulant. The exact mechanism of action in attention deficit hyperactivity disorder (ADHD) is unknown, but it is thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron, increasing their levels in the extraneuronal space.
Methylphenidate is a central nervous system stimulant that inhibits the reuptake of dopamine and norepinephrine into presynaptic neurons, increasing their concentrations in the synaptic cleft. It also acts as a weak agonist at serotonin receptors.
Initial: 39.2 mg oral once daily in the morning; titrate weekly by 19.6 mg increments as needed; maximum dose: 78.4 mg once daily.
Initial: 10-20 mg orally once daily in the morning. May increase by 10-20 mg at weekly intervals. Maximum: 60 mg/day.
None Documented
None Documented
Serdexmethylphenidate: 1.5 hours; dexmethylphenidate: 3.5 hours. The terminal half-life of total dexmethylphenidate after AZSTARYS is approximately 6.5 hours, supporting once-daily dosing.
Terminal elimination half-life: 3-6 hours (mean 4.5 hours) for methylphenidate; clinical context: requires multiple daily dosing or extended-release formulation.
Renal: 90% (primarily as metabolites, with 50-70% as the major metabolite (-)-phensuximide glucuronide). Fecal: <5%.
Renal (80% as metabolites, <1% unchanged); fecal (10-20%) via biliary elimination.
Category C
Category C
CNS Stimulant
CNS Stimulant